LymphedemaV1, PascalFrancis, Corpus, bibRecord, 000091

Upper-Body Morbidity After Breast Cancer*: Incidence and Evidence for Evaluation, Prevention, and Management Within a Prospective Surveillance Model of Care

Identifieur interne : 000091 ( PascalFrancis/Corpus ); précédent : 000090; suivant : 000092

Upper-Body Morbidity After Breast Cancer*: Incidence and Evidence for Evaluation, Prevention, and Management Within a Prospective Surveillance Model of Care

Auteurs : Sandra C. Hayes ; Karin Johansson ; Nicole L. Stout ; Robert Prosnitz ; Jane M. Armer ; Sheryl Gabram ; Kathryn H. Schmitz

Source :

Cancer [ 0008-543X ] ; 2012.

RBID : Pascal:12-0207324

Descripteurs français

Pascal (Inist)
- Cancer du sein, Morbidité, Incidence, Lymphoedème, Epidémiologie, Prévention, Conduite à tenir, Prospective, Surveillance, Modèle, Soin, Traitement, Cancérologie.

English descriptors

KwdEn :
- Breast cancer, Cancerology, Care, Clinical management, Epidemiology, Incidence, Lymphedema, Models, Morbidity, Prevention, Prospective, Surveillance, Treatment.

Abstract

The purpose of this paper is to review the incidence of upper-body morbidity (arm and breast symptoms, impairments, and lymphedema), methods for diagnosis, and prevention and treatment strategies. It was also the purpose to highlight the evidence base for integration of prospective surveillance for upper-body morbidity within standard clinical care of women with breast cancer. Between 10% and 64% of women report upper-body symptoms between 6 months and 3 years after breast cancer, and approximately 20% develop lymphedema. Symptoms remain common into longer-term survivorship, and although lymphedema may be transient for some, those who present with mild lymphedema are at increased risk of developing moderate to severe lymphedema. The etiology of morbidity seems to be multifactorial, with the most consistent risk factors being those associated with extent of treatment. However, known risk factors cannot reliably distinguish between those who will and will not develop upper-body morbidity. Upper-body morbidity may be treatable with physical therapy. There is also evidence in support of integrating regular surveillance for upper-body morbidity into the routine care provided to women with breast cancer, with early diagnosis potentially contributing to more effective management and prevention of progression of these conditions.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0008-543X`
A02	`01`			`@0 CANCAR`
A03		`1`		`@0 Cancer`
A05				`@2 118`
A06				`@2 8 @3 SUP`
A08	`01`	`1`	`ENG`	`@1 Upper-Body Morbidity After Breast Cancer^*: Incidence and Evidence for Evaluation, Prevention, and Management Within a Prospective Surveillance Model of Care`
A09	`01`	`1`	`ENG`	`@1 A Prospective Surveillance Model for Rehabilitation for Women With Breast Cancer`
A11	`01`	`1`		`@1 HAYES (Sandra C.)`
A11	`02`	`1`		`@1 JOHANSSON (Karin)`
A11	`03`	`1`		`@1 STOUT (Nicole L.)`
A11	`04`	`1`		`@1 PROSNITZ (Robert)`
A11	`05`	`1`		`@1 ARMER (Jane M.)`
A11	`06`	`1`		`@1 GABRAM (Sheryl)`
A11	`07`	`1`		`@1 SCHMITZ (Kathryn H.)`
A12	`01`	`1`		`@1 ANDREWS (Kimberly) @9 ed.`
A12	`02`	`1`		`@1 BINKLEY (Jill M.) @9 ed.`
A12	`03`	`1`		`@1 SCHMITZ (Kathryn H.) @9 ed.`
A12	`04`	`1`		`@1 SMITH (Robert A.) @9 ed.`
A12	`05`	`1`		`@1 STOUT (Nicole L.) @9 ed.`
A14	`01`			`@1 Queensland University of Technology, Institute of Health and Biomedical Innovation, School of Public Health @2 Brisbane @3 AUS @Z 1 aut.`
A14	`02`			`@1 Department of Oncology, Lund University Hospital @2 Lund @3 SWE @Z 2 aut.`
A14	`03`			`@1 Breast Care Center, Walter Reed National Military Medical Center @2 Bethesda, Maryland @3 USA @Z 3 aut.`
A14	`04`			`@1 Department of Radiation Oncology, University of Pennsylvania @2 Philadelphia, Pennsylvania @3 USA @Z 4 aut.`
A14	`05`			`@1 Sinclair School of Nursing, University of Missouri @2 Columbia, Missouri @3 USA @Z 5 aut.`
A14	`06`			`@1 Winship Cancer Institute of Emory University @2 Atlanta, Georgia @3 USA @Z 6 aut.`
A14	`07`			`@1 Department of Biostatistics and Epidemiology, University of Pennsylvania @2 Philadelphia, Pennsylvania @3 USA @Z 7 aut.`
A15	`01`			`@1 American Cancer Society @2 Atlanta, Georgia @3 USA @Z 1 aut. @Z 4 aut.`
A15	`02`			`@1 TurningPoint Women's Healthcare @2 Alpharetta, Georgia @3 USA @Z 2 aut.`
A15	`03`			`@1 Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine @2 Philadelphia, Pennsylvania @3 USA @Z 3 aut.`
A15	`04`			`@1 Breast Cancer Department, Walter Reed National Military Medical Center @2 Bethesda, Maryland @3 USA @Z 5 aut.`
A20				`@1 2237-2249`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 2701 @5 354000509308750060`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 156 ref.`
A47	`01`	`1`		`@0 12-0207324`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Cancer`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The purpose of this paper is to review the incidence of upper-body morbidity (arm and breast symptoms, impairments, and lymphedema), methods for diagnosis, and prevention and treatment strategies. It was also the purpose to highlight the evidence base for integration of prospective surveillance for upper-body morbidity within standard clinical care of women with breast cancer. Between 10% and 64% of women report upper-body symptoms between 6 months and 3 years after breast cancer, and approximately 20% develop lymphedema. Symptoms remain common into longer-term survivorship, and although lymphedema may be transient for some, those who present with mild lymphedema are at increased risk of developing moderate to severe lymphedema. The etiology of morbidity seems to be multifactorial, with the most consistent risk factors being those associated with extent of treatment. However, known risk factors cannot reliably distinguish between those who will and will not develop upper-body morbidity. Upper-body morbidity may be treatable with physical therapy. There is also evidence in support of integrating regular surveillance for upper-body morbidity into the routine care provided to women with breast cancer, with early diagnosis potentially contributing to more effective management and prevention of progression of these conditions.
C02	`01`	`X`		`@0 002B04`
C02	`02`	`X`		`@0 002B20E02`
C03	`01`	`X`	`FRE`	`@0 Cancer du sein @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Breast cancer @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Cáncer del pecho @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Morbidité @5 02`
C03	`02`	`X`	`ENG`	`@0 Morbidity @5 02`
C03	`02`	`X`	`SPA`	`@0 Morbilidad @5 02`
C03	`03`	`X`	`FRE`	`@0 Incidence @5 03`
C03	`03`	`X`	`ENG`	`@0 Incidence @5 03`
C03	`03`	`X`	`SPA`	`@0 Incidencia @5 03`
C03	`04`	`X`	`FRE`	`@0 Lymphoedème @5 04`
C03	`04`	`X`	`ENG`	`@0 Lymphedema @5 04`
C03	`04`	`X`	`SPA`	`@0 Linfedema @5 04`
C03	`05`	`X`	`FRE`	`@0 Epidémiologie @5 05`
C03	`05`	`X`	`ENG`	`@0 Epidemiology @5 05`
C03	`05`	`X`	`SPA`	`@0 Epidemiología @5 05`
C03	`06`	`X`	`FRE`	`@0 Prévention @5 06`
C03	`06`	`X`	`ENG`	`@0 Prevention @5 06`
C03	`06`	`X`	`SPA`	`@0 Prevención @5 06`
C03	`07`	`X`	`FRE`	`@0 Conduite à tenir @5 08`
C03	`07`	`X`	`ENG`	`@0 Clinical management @5 08`
C03	`07`	`X`	`SPA`	`@0 Actitud médica @5 08`
C03	`08`	`X`	`FRE`	`@0 Prospective @5 09`
C03	`08`	`X`	`ENG`	`@0 Prospective @5 09`
C03	`08`	`X`	`SPA`	`@0 Prospectiva @5 09`
C03	`09`	`X`	`FRE`	`@0 Surveillance @5 11`
C03	`09`	`X`	`ENG`	`@0 Surveillance @5 11`
C03	`09`	`X`	`SPA`	`@0 Vigilancia @5 11`
C03	`10`	`X`	`FRE`	`@0 Modèle @5 12`
C03	`10`	`X`	`ENG`	`@0 Models @5 12`
C03	`10`	`X`	`SPA`	`@0 Modelo @5 12`
C03	`11`	`X`	`FRE`	`@0 Soin @5 17`
C03	`11`	`X`	`ENG`	`@0 Care @5 17`
C03	`11`	`X`	`SPA`	`@0 Cuidado @5 17`
C03	`12`	`X`	`FRE`	`@0 Traitement @5 18`
C03	`12`	`X`	`ENG`	`@0 Treatment @5 18`
C03	`12`	`X`	`SPA`	`@0 Tratamiento @5 18`
C03	`13`	`X`	`FRE`	`@0 Cancérologie @5 19`
C03	`13`	`X`	`ENG`	`@0 Cancerology @5 19`
C03	`13`	`X`	`SPA`	`@0 Cancerología @5 19`
C07	`01`	`X`	`FRE`	`@0 Tumeur maligne @2 NM @5 37`
C07	`01`	`X`	`ENG`	`@0 Malignant tumor @2 NM @5 37`
C07	`01`	`X`	`SPA`	`@0 Tumor maligno @2 NM @5 37`
C07	`02`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`02`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`02`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`03`	`X`	`FRE`	`@0 Pathologie de la glande mammaire @2 NM @5 38`
C07	`03`	`X`	`ENG`	`@0 Mammary gland diseases @2 NM @5 38`
C07	`03`	`X`	`SPA`	`@0 Glándula mamaria patología @2 NM @5 38`
C07	`04`	`X`	`FRE`	`@0 Pathologie du sein @2 NM @5 39`
C07	`04`	`X`	`ENG`	`@0 Breast disease @2 NM @5 39`
C07	`04`	`X`	`SPA`	`@0 Seno patología @2 NM @5 39`
C07	`05`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 40`
C07	`05`	`X`	`ENG`	`@0 Cardiovascular disease @5 40`
C07	`05`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 40`
C07	`06`	`X`	`FRE`	`@0 Pathologie des vaisseaux lymphatiques @5 41`
C07	`06`	`X`	`ENG`	`@0 Lymphatic vessel disease @5 41`
C07	`06`	`X`	`SPA`	`@0 Linfático patología @5 41`
N21				`@1 163`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 12-0207324 INIST
ET :	Upper-Body Morbidity After Breast Cancer^*: Incidence and Evidence for Evaluation, Prevention, and Management Within a Prospective Surveillance Model of Care
AU :	HAYES (Sandra C.); JOHANSSON (Karin); STOUT (Nicole L.); PROSNITZ (Robert); ARMER (Jane M.); GABRAM (Sheryl); SCHMITZ (Kathryn H.); ANDREWS (Kimberly); BINKLEY (Jill M.); SCHMITZ (Kathryn H.); SMITH (Robert A.); STOUT (Nicole L.)
AF :	Queensland University of Technology, Institute of Health and Biomedical Innovation, School of Public Health/Brisbane/Australie (1 aut.); Department of Oncology, Lund University Hospital/Lund/Suède (2 aut.); Breast Care Center, Walter Reed National Military Medical Center/Bethesda, Maryland/Etats-Unis (3 aut.); Department of Radiation Oncology, University of Pennsylvania/Philadelphia, Pennsylvania/Etats-Unis (4 aut.); Sinclair School of Nursing, University of Missouri/Columbia, Missouri/Etats-Unis (5 aut.); Winship Cancer Institute of Emory University/Atlanta, Georgia/Etats-Unis (6 aut.); Department of Biostatistics and Epidemiology, University of Pennsylvania/Philadelphia, Pennsylvania/Etats-Unis (7 aut.); American Cancer Society/Atlanta, Georgia/Etats-Unis (1 aut., 4 aut.); TurningPoint Women's Healthcare/Alpharetta, Georgia/Etats-Unis (2 aut.); Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine/Philadelphia, Pennsylvania/Etats-Unis (3 aut.); Breast Cancer Department, Walter Reed National Military Medical Center/Bethesda, Maryland/Etats-Unis (5 aut.)
DT :	Publication en série; Niveau analytique
SO :	Cancer; ISSN 0008-543X; Coden CANCAR; Etats-Unis; Da. 2012; Vol. 118; No. 8 SUP; Pp. 2237-2249; Bibl. 156 ref.
LA :	Anglais
EA :	The purpose of this paper is to review the incidence of upper-body morbidity (arm and breast symptoms, impairments, and lymphedema), methods for diagnosis, and prevention and treatment strategies. It was also the purpose to highlight the evidence base for integration of prospective surveillance for upper-body morbidity within standard clinical care of women with breast cancer. Between 10% and 64% of women report upper-body symptoms between 6 months and 3 years after breast cancer, and approximately 20% develop lymphedema. Symptoms remain common into longer-term survivorship, and although lymphedema may be transient for some, those who present with mild lymphedema are at increased risk of developing moderate to severe lymphedema. The etiology of morbidity seems to be multifactorial, with the most consistent risk factors being those associated with extent of treatment. However, known risk factors cannot reliably distinguish between those who will and will not develop upper-body morbidity. Upper-body morbidity may be treatable with physical therapy. There is also evidence in support of integrating regular surveillance for upper-body morbidity into the routine care provided to women with breast cancer, with early diagnosis potentially contributing to more effective management and prevention of progression of these conditions.
CC :	002B04; 002B20E02
FD :	Cancer du sein; Morbidité; Incidence; Lymphoedème; Epidémiologie; Prévention; Conduite à tenir; Prospective; Surveillance; Modèle; Soin; Traitement; Cancérologie
FG :	Tumeur maligne; Cancer; Pathologie de la glande mammaire; Pathologie du sein; Pathologie de l'appareil circulatoire; Pathologie des vaisseaux lymphatiques
ED :	Breast cancer; Morbidity; Incidence; Lymphedema; Epidemiology; Prevention; Clinical management; Prospective; Surveillance; Models; Care; Treatment; Cancerology
EG :	Malignant tumor; Cancer; Mammary gland diseases; Breast disease; Cardiovascular disease; Lymphatic vessel disease
SD :	Cáncer del pecho; Morbilidad; Incidencia; Linfedema; Epidemiología; Prevención; Actitud médica; Prospectiva; Vigilancia; Modelo; Cuidado; Tratamiento; Cancerología
LO :	INIST-2701.354000509308750060
ID :	12-0207324

Links to Exploration step

Pascal:12-0207324

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Upper-Body Morbidity After Breast Cancer<sup>*</sup>
: Incidence and Evidence for Evaluation, Prevention, and Management Within a Prospective Surveillance Model of Care</title>
<author><name sortKey="Hayes, Sandra C" sort="Hayes, Sandra C" uniqKey="Hayes S" first="Sandra C." last="Hayes">Sandra C. Hayes</name>
<affiliation><inist:fA14 i1="01"><s1>Queensland University of Technology, Institute of Health and Biomedical Innovation, School of Public Health</s1>
<s2>Brisbane</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Johansson, Karin" sort="Johansson, Karin" uniqKey="Johansson K" first="Karin" last="Johansson">Karin Johansson</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Oncology, Lund University Hospital</s1>
<s2>Lund</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stout, Nicole L" sort="Stout, Nicole L" uniqKey="Stout N" first="Nicole L." last="Stout">Nicole L. Stout</name>
<affiliation><inist:fA14 i1="03"><s1>Breast Care Center, Walter Reed National Military Medical Center</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Prosnitz, Robert" sort="Prosnitz, Robert" uniqKey="Prosnitz R" first="Robert" last="Prosnitz">Robert Prosnitz</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Radiation Oncology, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Armer, Jane M" sort="Armer, Jane M" uniqKey="Armer J" first="Jane M." last="Armer">Jane M. Armer</name>
<affiliation><inist:fA14 i1="05"><s1>Sinclair School of Nursing, University of Missouri</s1>
<s2>Columbia, Missouri</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gabram, Sheryl" sort="Gabram, Sheryl" uniqKey="Gabram S" first="Sheryl" last="Gabram">Sheryl Gabram</name>
<affiliation><inist:fA14 i1="06"><s1>Winship Cancer Institute of Emory University</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schmitz, Kathryn H" sort="Schmitz, Kathryn H" uniqKey="Schmitz K" first="Kathryn H." last="Schmitz">Kathryn H. Schmitz</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Biostatistics and Epidemiology, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0207324</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0207324 INIST</idno>
<idno type="RBID">Pascal:12-0207324</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000091</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Upper-Body Morbidity After Breast Cancer<sup>*</sup>
: Incidence and Evidence for Evaluation, Prevention, and Management Within a Prospective Surveillance Model of Care</title>
<author><name sortKey="Hayes, Sandra C" sort="Hayes, Sandra C" uniqKey="Hayes S" first="Sandra C." last="Hayes">Sandra C. Hayes</name>
<affiliation><inist:fA14 i1="01"><s1>Queensland University of Technology, Institute of Health and Biomedical Innovation, School of Public Health</s1>
<s2>Brisbane</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Johansson, Karin" sort="Johansson, Karin" uniqKey="Johansson K" first="Karin" last="Johansson">Karin Johansson</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Oncology, Lund University Hospital</s1>
<s2>Lund</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stout, Nicole L" sort="Stout, Nicole L" uniqKey="Stout N" first="Nicole L." last="Stout">Nicole L. Stout</name>
<affiliation><inist:fA14 i1="03"><s1>Breast Care Center, Walter Reed National Military Medical Center</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Prosnitz, Robert" sort="Prosnitz, Robert" uniqKey="Prosnitz R" first="Robert" last="Prosnitz">Robert Prosnitz</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Radiation Oncology, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Armer, Jane M" sort="Armer, Jane M" uniqKey="Armer J" first="Jane M." last="Armer">Jane M. Armer</name>
<affiliation><inist:fA14 i1="05"><s1>Sinclair School of Nursing, University of Missouri</s1>
<s2>Columbia, Missouri</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gabram, Sheryl" sort="Gabram, Sheryl" uniqKey="Gabram S" first="Sheryl" last="Gabram">Sheryl Gabram</name>
<affiliation><inist:fA14 i1="06"><s1>Winship Cancer Institute of Emory University</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schmitz, Kathryn H" sort="Schmitz, Kathryn H" uniqKey="Schmitz K" first="Kathryn H." last="Schmitz">Kathryn H. Schmitz</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Biostatistics and Epidemiology, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Cancer</title>
<title level="j" type="abbreviated">Cancer</title>
<idno type="ISSN">0008-543X</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Cancer</title>
<title level="j" type="abbreviated">Cancer</title>
<idno type="ISSN">0008-543X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Breast cancer</term>
<term>Cancerology</term>
<term>Care</term>
<term>Clinical management</term>
<term>Epidemiology</term>
<term>Incidence</term>
<term>Lymphedema</term>
<term>Models</term>
<term>Morbidity</term>
<term>Prevention</term>
<term>Prospective</term>
<term>Surveillance</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cancer du sein</term>
<term>Morbidité</term>
<term>Incidence</term>
<term>Lymphoedème</term>
<term>Epidémiologie</term>
<term>Prévention</term>
<term>Conduite à tenir</term>
<term>Prospective</term>
<term>Surveillance</term>
<term>Modèle</term>
<term>Soin</term>
<term>Traitement</term>
<term>Cancérologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The purpose of this paper is to review the incidence of upper-body morbidity (arm and breast symptoms, impairments, and lymphedema), methods for diagnosis, and prevention and treatment strategies. It was also the purpose to highlight the evidence base for integration of prospective surveillance for upper-body morbidity within standard clinical care of women with breast cancer. Between 10% and 64% of women report upper-body symptoms between 6 months and 3 years after breast cancer, and approximately 20% develop lymphedema. Symptoms remain common into longer-term survivorship, and although lymphedema may be transient for some, those who present with mild lymphedema are at increased risk of developing moderate to severe lymphedema. The etiology of morbidity seems to be multifactorial, with the most consistent risk factors being those associated with extent of treatment. However, known risk factors cannot reliably distinguish between those who will and will not develop upper-body morbidity. Upper-body morbidity may be treatable with physical therapy. There is also evidence in support of integrating regular surveillance for upper-body morbidity into the routine care provided to women with breast cancer, with early diagnosis potentially contributing to more effective management and prevention of progression of these conditions.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0008-543X</s0>
</fA01>
<fA02 i1="01"><s0>CANCAR</s0>
</fA02>
<fA03 i2="1"><s0>Cancer</s0>
</fA03>
<fA05><s2>118</s2>
</fA05>
<fA06><s2>8</s2>
<s3>SUP</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Upper-Body Morbidity After Breast Cancer<sup>*</sup>
: Incidence and Evidence for Evaluation, Prevention, and Management Within a Prospective Surveillance Model of Care</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>A Prospective Surveillance Model for Rehabilitation for Women With Breast Cancer</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>HAYES (Sandra C.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>JOHANSSON (Karin)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>STOUT (Nicole L.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PROSNITZ (Robert)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ARMER (Jane M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GABRAM (Sheryl)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SCHMITZ (Kathryn H.)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>ANDREWS (Kimberly)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>BINKLEY (Jill M.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="03" i2="1"><s1>SCHMITZ (Kathryn H.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="04" i2="1"><s1>SMITH (Robert A.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="05" i2="1"><s1>STOUT (Nicole L.)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Queensland University of Technology, Institute of Health and Biomedical Innovation, School of Public Health</s1>
<s2>Brisbane</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Oncology, Lund University Hospital</s1>
<s2>Lund</s2>
<s3>SWE</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Breast Care Center, Walter Reed National Military Medical Center</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Radiation Oncology, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Sinclair School of Nursing, University of Missouri</s1>
<s2>Columbia, Missouri</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Winship Cancer Institute of Emory University</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Biostatistics and Epidemiology, University of Pennsylvania</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>American Cancer Society</s1>
<s2>Atlanta, Georgia</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>TurningPoint Women's Healthcare</s1>
<s2>Alpharetta, Georgia</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA15 i1="03"><s1>Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine</s1>
<s2>Philadelphia, Pennsylvania</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA15>
<fA15 i1="04"><s1>Breast Cancer Department, Walter Reed National Military Medical Center</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA15>
<fA20><s1>2237-2249</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>2701</s2>
<s5>354000509308750060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>156 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0207324</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Cancer</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The purpose of this paper is to review the incidence of upper-body morbidity (arm and breast symptoms, impairments, and lymphedema), methods for diagnosis, and prevention and treatment strategies. It was also the purpose to highlight the evidence base for integration of prospective surveillance for upper-body morbidity within standard clinical care of women with breast cancer. Between 10% and 64% of women report upper-body symptoms between 6 months and 3 years after breast cancer, and approximately 20% develop lymphedema. Symptoms remain common into longer-term survivorship, and although lymphedema may be transient for some, those who present with mild lymphedema are at increased risk of developing moderate to severe lymphedema. The etiology of morbidity seems to be multifactorial, with the most consistent risk factors being those associated with extent of treatment. However, known risk factors cannot reliably distinguish between those who will and will not develop upper-body morbidity. Upper-body morbidity may be treatable with physical therapy. There is also evidence in support of integrating regular surveillance for upper-body morbidity into the routine care provided to women with breast cancer, with early diagnosis potentially contributing to more effective management and prevention of progression of these conditions.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B20E02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Cancer du sein</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Breast cancer</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Cáncer del pecho</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Morbidité</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Morbidity</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Morbilidad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Incidence</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Incidence</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Incidencia</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Lymphoedème</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Lymphedema</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Linfedema</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Epidémiologie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Epidemiology</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Epidemiología</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Prévention</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Prevention</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Prevención</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Conduite à tenir</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Clinical management</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Actitud médica</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Prospective</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Prospective</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Prospectiva</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Surveillance</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Surveillance</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Vigilancia</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Modèle</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Models</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Modelo</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Soin</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Care</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Cuidado</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Traitement</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Treatment</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Cancérologie</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Cancerology</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Cancerología</s0>
<s5>19</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie de la glande mammaire</s0>
<s2>NM</s2>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Mammary gland diseases</s0>
<s2>NM</s2>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Glándula mamaria patología</s0>
<s2>NM</s2>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du sein</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Breast disease</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Seno patología</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie des vaisseaux lymphatiques</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Linfático patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>163</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 12-0207324 INIST</NO>
<ET>Upper-Body Morbidity After Breast Cancer<sup>*</sup>
: Incidence and Evidence for Evaluation, Prevention, and Management Within a Prospective Surveillance Model of Care</ET>
<AU>HAYES (Sandra C.); JOHANSSON (Karin); STOUT (Nicole L.); PROSNITZ (Robert); ARMER (Jane M.); GABRAM (Sheryl); SCHMITZ (Kathryn H.); ANDREWS (Kimberly); BINKLEY (Jill M.); SCHMITZ (Kathryn H.); SMITH (Robert A.); STOUT (Nicole L.)</AU>
<AF>Queensland University of Technology, Institute of Health and Biomedical Innovation, School of Public Health/Brisbane/Australie (1 aut.); Department of Oncology, Lund University Hospital/Lund/Suède (2 aut.); Breast Care Center, Walter Reed National Military Medical Center/Bethesda, Maryland/Etats-Unis (3 aut.); Department of Radiation Oncology, University of Pennsylvania/Philadelphia, Pennsylvania/Etats-Unis (4 aut.); Sinclair School of Nursing, University of Missouri/Columbia, Missouri/Etats-Unis (5 aut.); Winship Cancer Institute of Emory University/Atlanta, Georgia/Etats-Unis (6 aut.); Department of Biostatistics and Epidemiology, University of Pennsylvania/Philadelphia, Pennsylvania/Etats-Unis (7 aut.); American Cancer Society/Atlanta, Georgia/Etats-Unis (1 aut., 4 aut.); TurningPoint Women's Healthcare/Alpharetta, Georgia/Etats-Unis (2 aut.); Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine/Philadelphia, Pennsylvania/Etats-Unis (3 aut.); Breast Cancer Department, Walter Reed National Military Medical Center/Bethesda, Maryland/Etats-Unis (5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Cancer; ISSN 0008-543X; Coden CANCAR; Etats-Unis; Da. 2012; Vol. 118; No. 8 SUP; Pp. 2237-2249; Bibl. 156 ref.</SO>
<LA>Anglais</LA>
<EA>The purpose of this paper is to review the incidence of upper-body morbidity (arm and breast symptoms, impairments, and lymphedema), methods for diagnosis, and prevention and treatment strategies. It was also the purpose to highlight the evidence base for integration of prospective surveillance for upper-body morbidity within standard clinical care of women with breast cancer. Between 10% and 64% of women report upper-body symptoms between 6 months and 3 years after breast cancer, and approximately 20% develop lymphedema. Symptoms remain common into longer-term survivorship, and although lymphedema may be transient for some, those who present with mild lymphedema are at increased risk of developing moderate to severe lymphedema. The etiology of morbidity seems to be multifactorial, with the most consistent risk factors being those associated with extent of treatment. However, known risk factors cannot reliably distinguish between those who will and will not develop upper-body morbidity. Upper-body morbidity may be treatable with physical therapy. There is also evidence in support of integrating regular surveillance for upper-body morbidity into the routine care provided to women with breast cancer, with early diagnosis potentially contributing to more effective management and prevention of progression of these conditions.</EA>
<CC>002B04; 002B20E02</CC>
<FD>Cancer du sein; Morbidité; Incidence; Lymphoedème; Epidémiologie; Prévention; Conduite à tenir; Prospective; Surveillance; Modèle; Soin; Traitement; Cancérologie</FD>
<FG>Tumeur maligne; Cancer; Pathologie de la glande mammaire; Pathologie du sein; Pathologie de l'appareil circulatoire; Pathologie des vaisseaux lymphatiques</FG>
<ED>Breast cancer; Morbidity; Incidence; Lymphedema; Epidemiology; Prevention; Clinical management; Prospective; Surveillance; Models; Care; Treatment; Cancerology</ED>
<EG>Malignant tumor; Cancer; Mammary gland diseases; Breast disease; Cardiovascular disease; Lymphatic vessel disease</EG>
<SD>Cáncer del pecho; Morbilidad; Incidencia; Linfedema; Epidemiología; Prevención; Actitud médica; Prospectiva; Vigilancia; Modelo; Cuidado; Tratamiento; Cancerología</SD>
<LO>INIST-2701.354000509308750060</LO>
<ID>12-0207324</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000091 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000091 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:12-0207324
   |texte=   Upper-Body Morbidity After Breast Cancer*: Incidence and Evidence for Evaluation, Prevention, and Management Within a Prospective Surveillance Model of Care
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Upper-Body Morbidity After Breast Cancer*: Incidence and Evidence for Evaluation, Prevention, and Management Within a Prospective Surveillance Model of Care

Upper-Body Morbidity After Breast Cancer*: Incidence and Evidence for Evaluation, Prevention, and Management Within a Prospective Surveillance Model of Care

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri